Research programme: cancer immunotherapeutics - Pfizer

Drug Profile

Research programme: cancer immunotherapeutics - Pfizer

Alternative Names: Anti-CD134 monoclonal antibody - Pfizer; Anti-CD3 anti-BCMA bispecific antibody; Anti-macrophage colony stimulating factor antibody- Pfizer; anti-MCSF-antibody- Pfizer; Anti-OX40 monoclonal antibody - Pfizer; Anti-PD1 monoclonal antibody - Pfizer; CCR2-inhibitor- Pfizer; Prostate cancer vaccine - Pfizer

Latest Information Update: 14 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Bispecific antibodies; Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; OX40 receptor antagonists; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Prostate cancer

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Cancer presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 19 Nov 2014 Pfizer and Merck KGaA enter into a collaboration to advance Pfizer's anti-PD1 antibody into phase I trials
  • 17 Nov 2014 Preclinical trials in Cancer in USA (Parenteral) prior to November 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top